key: cord-0895088-dvsgky20 authors: Cruz, Virgínia Barbeitos; Júnior, Luiz Fernando Fróes Fleury; Kobal, Christiane Reis; da Silva, Nilzio Antonio title: Does sensitization by SARS-CoV-2 immune complexes trigger DRESS syndrome? date: 2022-02-28 journal: Braz J Infect Dis DOI: 10.1016/j.bjid.2022.102337 sha: fa3bbccddb435cdc55fdb5a9df7b246a34d3a652 doc_id: 895088 cord_uid: dvsgky20 The diagnosis of coronavirus disease (COVID-19) has been a great challenge since the infection affects not only the respiratory system, but also different organs, given the intense inflammatory and autoimmune reaction triggered by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Herein we present a case of a 36-year-old male patient, with some comorbidities and previous use of carbamazepine, who developed a severe condition triggered by COVID-19, including extensive exfoliative erythroderma and severe impairment of liver function, which lasted approximately 80 days. Extra-respiratory manifestations of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection have been described and are especially important for diagnostic and epidemiological purposes, once most infected people are asymptomatic. 1,2 Among these manifestations, dermatoses have been observed in approximately 20.4% of the patients diagnosed with coronavirus disease (COVID- 19) , associated with changes caused by the virus itself or by worsening underlying dermatological conditions. 2 Cutaneous manifestations related to COVID- 19 have not been frequently reported, likely due to underdiagnosis. However, so far, six large groups of possible lesions have been described: maculopapular rash, urticaria, chilblain, vesicular lesions, livedo reticularis, and petechiae. 3 Some idiosyncratic reactions to the drugs used to treat COVID-19 have also been reported. In these cases, the possible mechanisms involved could be lymphocytic vasculitis induced by viral particles, deposition of immune complexes, or skin microvessel thrombosis. Erythema, urticaria, contact dermatitis, varicella-like rash, erythroderma, livedo reticularis, lichenoid photodermatitis, and acute generalized exanthematous pustulosis are among the reported reactions. 1, 2 Gastrointestinal manifestations have also been found in 79% of the patients with COVID-19, although their pathophysiology remains poorly understood. The large expression of angiotensin-converting enzyme 2 on the gastric, duodenal, and rectal epithelia glandular cells, as well as on the endothelial cells of the small intestine, is thought to be one of the mechanisms involved. The most frequent symptoms are anorexia, abdominal pain, nausea, vomiting, diarrhea, and gastrointestinal bleeding. [4] [5] [6] About one third of the patients infected with SARS-CoV-2, especially males, between 35 and 56 years old, have liver dysfunction. Pre-existing liver diseases, elevated alanine aminotransferase and transaminase levels, thrombocytopenia, and hypoalbuminemia have been pointed out as risk factors for the tissue damage observed in these individuals. Intense inflammatory reaction and autoimmune 3 sensitization, mediated by toll-like receptors and killer T lymphocytes, are among the possible pathogenic mechanisms. 7, 8 Herein we present a case of a young, obese, male patient undergoing alcohol addiction treatment, diagnosed with COVID-19 due to community transmission, with quickly serious gastrointestinal manifestations, severe impairment of liver function, in addition to exuberant dermatologic manifestations, with no respiratory symptoms. On April 1, 2020 [Day 1 (D1)], a 36-year-old male patient, with several comorbidities (obesity, hepatic steatosis, hypertension, panic disorder, and alcohol addiction), and under treatment with carbamazepine (400 mg/day), escitalopram (20 mg/day), amlodipine (50 mg/day), losartan (50 mg/day), and nebivolol (5 mg/day), sought for assistance in private practice due to the following symptoms: mild to moderate abdominal pain, diffuse, associated with dyspepsia, belching, with no nausea, vomiting, or fever. On D3, the pain worsened and was described by the patient as left thoracolumbar colic, radiating to the periumbilical region and testicles, associated with important abdominal distension. He was checked in the hospital with normal temperature, preserved peristalsis, no change in urinary or intestinal functions, nonnodular liver, palpable at 3.0 cm from the costal margin, and non-palpable axillary, inguinal, or cervical lymph nodes. In addition to oral rehydrating solutions, the prescribed treatment included fexofenadine hydrochloride (180 mg/day), paracetamol (1,500 mg/day), dipyrone (1,000 mg/day), codeine (30 mg/day), and scopolamine solution + dipyrone (30 mg + 750 mg/day). On the same day, he underwent total abdomen computed tomography (CT) that revealed hepatic steatosis, kidney stones, bowel loops normal in diameter, normal peritoneum, retroperitoneum, gall bladder, and bile ducts. On D7, a cholangioresonance confirmed hepatic steatosis and showed that the liver was slightly enlarged, with sparse infracentimetric cysts, adenomyomatosis at the bottom of the gall bladder, intra and extrahepatic bile ducts with no dilations, normal pancreas, pancreatic ducts, and spleen, normally positioned kidneys, bilateral single kidney microcysts, calyceal system with no dilations, single lymph node in the hepatic COVID-19 has been considered a systemic disease, capable of generating breakdown and rapid exhaustion of defense and autoimmunity mechanisms, with the most diverse degrees of involvement of different tissues and systems other than just the respiratory system, and often dissociated from it. 6, 9 In the present report, the first manifestation of SARS-CoV-2 infection was abdominal pain, radiating to the lumbar region and testicles, suggesting movement of kidney stone, not confirmed by imaging exams. Similarly, another report described the case of a patient who was referred to the emergency department due to abdominal and testicular pain and was subsequently diagnosed with COVID-19. 10 Fever was not a striking sign of acute infectious disease in our patient. In a review article, 18.7% of the patients diagnosed with COVID-19 and admitted to hospital did not have fever. 11 As observed in another study carried out in Wuhan (China), 62.4% of those infected with COVID-19 who presented with gastrointestinal manifestations 6 alone or associated with respiratory impairment had no fever. 12 The patient of this case report had fever only during the staphylococcal skin infection. The severe cutaneous manifestation observed in our patient lasted 68 days, while the average duration related exclusively to COVID-19 is 10 days. 2 The idiosyncratic manifestations of carbamazepine, one of the drugs most often associated with the DRESS syndrome, generally last between three weeks and three months, with an average of eight weeks from the beginning of the exposure, sometimes precipitated by viral infection. 14 Our patient started using this drug three months before symptom onset. Recognition of the toxicity of carbamazepine, and its withdrawal, was delayed, which we attribute to the confusion generated by the great mimic power of SARS- This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors. Not applicable. Written informed consent was obtained from the patient. The authors declare no conflicts of interest. COVID-19 with dermatologic manifestations and implications: An unfolding conundrum Cutaneous manifestations of COVID-19: Report of three cases and a review of literature A comprehensive review of cutaneous manifestations associated with COVID-19 COVID-19 and the gastrointestinal tract: more than meets the eye Review article: gastrointestinal features in COVID-19 and the possibility of faecal transmission Extra-respiratory manifestations of COVID-19 Care of patients with liver disease during the COVID-19 pandemic: EASL-ESCMID position paper COVID-19 and liver dysfunction: current insights and emergent therapeutic strategies Perspectives on therapeutic neutralizing antibodies against the Novel Coronavirus SARS-CoV-2 Abdominal and testicular pain: An atypical presentation of COVID-19 The pathogenesis of coronavirus disease 2019 (COVID-19): evaluation and prevention Digestive symptoms in COVID-19 patients with mild disease severity: clinical presentation, stool viral RNA testing, and outcomes Drug-induced hypersensitivity syndrome (DiHS)/drug reaction with eosinophilia and systemic symptoms (DRESS): An update in 2019 Anticonvulsant hypersensitivity syndrome: an update A case of DRESS syndrome associated with carbamazepine treatment Recognition and management of severe cutaneous drug reactions Liver involvement in the drug reaction, eosinophilia, and systemic symptoms syndrome Virus reactivation in drug reaction with eosinophilia and systemic symptoms (Dress) results from a strong drug-specific immune response Drug reaction with eosinophilia and systemic symptoms (DRESS) in patients with COVID-19 Drug reaction with eosinofilia and systemic symptoms syndrome in a patient with COVID-19 Detection of SARS-CoV-2 in a case of DRESS by sulfasalazine: could there be a relationship with clinical importance? Histopathologic spectrum of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): a diagnosis that needs clinico-pathological correlation Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist? Basophil activation after nonsteroidal antiinflammatory drugs stimulation in patients with immediate hypersensitivity reactions to these drugs We thank the patient for his kind consent for the publication of this case.